Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.55) per share which met the analyst consensus estimate. This is a 685.71 percent decrease over losses of $(0.07) per share from the same period last
Benzinga · 20小时前
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcar
GlobeNewswire · 20小时前
Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?
Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 4天前
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
Nationally recognized leader in corporate life sciences transactionsSAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on